AdvanSix Q3 2026 slides: cash flow improves despite profit miss

AdvanSix Inc. (ASIX) reported Q3 2026 earnings with revenue up 15% YoY to $431M, but missed profitability expectations with an adjusted loss of $0.24 per share. Cash flow improved, with operating cash flow up $21M YoY to $48M. Shares fell 3.53% post-earnings.

Original reporting
Published Nov 4, 2026, 4:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 4:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$ASIX
Bearish
high confidence
Mentioned
$ASIX
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ASIXBearishMed
01

Why it matters

The earnings miss is the primary catalyst for the 3.5% share decline; cash flow strength may mitigate longer‑term concerns.

02

Market read

The report provides fresh earnings data that can affect trading decisions for ASIX and related chemical stocks.

03

What to watch

The new USDA FIELDS grant and upcoming credit facility provide longer‑term upside not reflected in the short‑term price move.

Relevance 7/10Novelty 8/10Timing: after market close

Background

AdvanSix reported Q3 2026 results, showing revenue growth but a profit miss and margin compression.

Company-level read

Ticker impact

$ASIXBearishHigh confidence
Context

Q3 2026 earnings miss with adjusted loss of $0.24 per share versus expectations of a $0.28 profit.

Expected impact

likely pressure as market prices in the earnings miss

Evidence & confidence

The loss and miss are primary new facts; investors typically react negatively to profit shortfalls.

Market effects

Chemicals sector may see modest pullback as raw material cost pressures are highlighted.

U.S. industrial stocks could face slight downside pressure.

Limited to investors with exposure to specialty chemicals and industrial commodities.

Counterpoint

Cash flow improvement and strong pricing could support a bounce if the market overreacts to the loss.

Key entities

  • AdvanSix Inc.

    Specialty chemicals manufacturer reporting Q3 2026 earnings.

Related articles

Med

AdvanSix Inc. Q3 2026 Earnings Call Summary

AdvanSix Inc. reported Q3 2026 earnings, highlighting 17% favorable pricing offsetting $65M raw material cost increases. The company maintained high operating rates, optimized production, and reduced fixed costs. It expects Q4 price-over-raws headwinds and a 2027 ammonium sulfate supply shortage. AdvanSix secured a $47M USDA grant for Project CENTURY and closed a $425M credit facility.

$ASIXMedAI 8/10

AdvanSix (ASIX) Q3 2026 Earnings Call Transcript

AdvanSix (ASIX) reported Q3 2026 sales of $431M, up 15% YoY, driven by pricing. Adjusted EBITDA was $15M, down $10M YoY. Ammonia sales expected to rise 25% for the year. Nylon resin production up 5% YoY. Company focuses on cost reduction, operational excellence, and disciplined capital deployment.

$ASIXHigh

AdvanSix stock slips 2% on third quarter earnings miss

AdvanSix Inc. (ASIX) reported Q3 earnings that missed expectations, with an adjusted loss per share of -$0.24 vs. $0.28 estimate. Revenue was $430.81M, up 15% YoY. Stock fell 2% in pre-market trading. The company cited strong commercial execution and pricing strategies to offset inflation. Adjusted EBITDA declined to $14.6M, while cash flow improved to $48M. ASIX refinanced its credit facility and declared a $0.16 quarterly dividend.

$ASIXHigh

ADVANSIX ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS

AdvanSix Inc. (ASIX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release ADVANSIX ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS 3Q26 Sales of $431 million, up 15% versus prior year 3Q26 Earnings Per Share of ($0.28); Adjusted Earnings Per Share of ($0.24) 3Q26 Cash Flow from Operations of $48 million, up $21 million versus p